Sanofi
SNY
$59.15
$1.452.51%
12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
---|---|---|---|---|---|
Revenue | 96.90% | 6.62% | -47.81% | 3.54% | |
Total Other Revenue | -27.99% | 0.79% | 69.65% | 20.86% | |
Total Revenue | 74.25% | 6.28% | -40.32% | 4.40% | |
Cost of Revenue | 52.69% | 2.76% | -34.51% | 8.30% | |
Gross Profit | 86.23% | 7.85% | -43.12% | 2.80% | |
SG&A Expenses | 126.69% | 1.87% | -58.58% | 5.36% | |
Depreciation & Amortization | 50.31% | -9.63% | -31.65% | -11.51% | |
Other Operating Expenses | -40.31% | 46.57% | 84.95% | 251.38% | |
Total Operating Expenses | 42.02% | 6.65% | -26.34% | 17.37% | |
Operating Income | 541.65% | 4.13% | -122.73% | -19.26% | |
Income Before Tax | 184.61% | -18.50% | -132.35% | 24.99% | |
Income Tax Expenses | 164.82% | 9.10% | -133.60% | 1.19% | |
Earnings from Continuing Operations | 190.58% | -23.67% | -131.99% | 31.87% | |
Earnings from Discontinued Operations | -- | -- | -- | -- | |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
Minority Interest in Earnings | -446.51% | 67.04% | 106.34% | -368.08% | |
Net Income | 208.99% | -23.31% | -121.02% | 31.38% | |
EBIT | 541.65% | 4.13% | -122.73% | -19.26% | |
EBITDA | 691.19% | 1.00% | -86.76% | -14.11% | |
EPS Basic | 208.24% | -23.27% | -121.17% | 31.41% | |
Normalized Basic EPS | -- | 2.80% | -- | -- | |
EPS Diluted | 208.24% | -23.65% | -121.17% | 31.41% | |
Normalized Diluted EPS | -- | 2.07% | -- | -- | |
Average Basic Shares Outstanding | 0.15% | -0.05% | -0.18% | -0.02% | |
Average Diluted Shares Outstanding | -0.22% | 0.66% | 0.19% | -0.02% | |
Dividend Per Share | 3.23% | -- | 11.29% | -- | |
Payout Ratio | -- | -- | -- | -- |